Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IFON, APPY, DYNT, PWRM, HIRU - Market Report From!



HIRU CORPORATION (Other OTC: HIRU.PK) subsidiary Shuangshi AHP Co.'s new production line and workshop are in their final stages. The new equipment is being put in place.

The company announced on June 17, during the second annual Shuangshi AHP Co. board meeting, that the management decided to invest and expand on the company's vaccination production. Since then, the company invested $3 million RMB into the development of the two new production lines: a line for large volume injections and a line for injection powder.

The next step of this project will be to install the air purification system necessary for these production lines. The air purification system is required for a successful operation of these volume and powder injection production lines.

The company is pleased with this progress of this project and looks forward to future growth.



Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

"We are very excited to be acquiring Rozetta-Cell Life Sciences," stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."


Dynatronics Corp. (Nasdaq:DYNT) announced results for its fiscal first quarter ended September 30, 2010. Sales for the quarter ended September 30, 2010 were $7,919,288, compared to $8,282,463 in the quarter ended September 30, 2009. Net income for the quarter ended September 30, 2010, was$17,012 ($.00 per common share), compared to $68,625 ($.01 per common share) for the same quarter in the prior fiscal year. Reduced sales for the quarter of $363,175 were offset by lower SG&A expenses. However, higher R&D costs contributed to lower overall profitability for the quarter ended September 30, 2010 compared to the same quarter of the prior year.

Dynatronics Corporation designs, manufactures, markets, and distributes physical medicine and aesthetic products primarily in the United States and Canada. The company offers physical medicine products, such as electrotherapy products for treating chronic intractable pain and/or acute post-traumatic pain, increasing local blood circulation, relaxation of muscle spasms, prevention or retardation of disuse atrophy, and muscle re-education.


AspenBio Pharma Inc. (Nasdaq:APPY) announced the receipt of a cash grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The $1.0 billion in funding and credits allocated to the QTDP Program is being distributed to companies with fewer than 250 employees whose research shows the greatest potential to result in new therapies that address areas of unmet medical need. The QTDP Program was designed to identify and support innovation. We are pleased that they recognize the potential of our AppyScore™ product — a novel, blood-based diagnostic test in development, designed to aid emergency department physicians in the difficult challenge of evaluating patients suspected of having appendicitis,” said Steve Lundy, AspenBio’s Chief Executive Officer and President. “This cash grant will help support our continued development activities.”

AspenBio Pharma, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of products that address un-met diagnostic and therapeutic needs. The Company’s research and development activities primarily focus on a human appendicitis blood-based test and bovine single-chain recombinant reproduction enhancement drugs.


Infosonics Corp. (Nasdaq:IFON) a provider of wireless handset solutions serving Latin America and Asia Pacific, announced results for its third quarter ended September 30, 2010. Although our results for the quarter were disappointing, we remain confident in our strategy,” said Joseph Ram, president and CEO of InfoSonics. “We’re rapidly transitioning our business from being primarily a distributor of wireless handsets in Latin America to being a designer and manufacturer of handsets serving both Latin America and other emerging markets. This quarter we experienced a significant drop in our legacy distribution business, but we are still in the investment and startup phase of our new Asia Pacific business. While we had significant expenses related to R&D and marketing during the quarter, we still believe the benefits of our new business are forthcoming, as evidenced by our October 19th announcement of the inaugural shipment of our new ruggedized R80 wireless handset to our first customer in China.”

InfoSonics Corporation distributes and provides wireless handsets and accessories in Central and South America. The company also designs, sources, and distributes entry level, mid-tier, and high-end products under the verykool name.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU)

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).